Plus Therapeutics (NASDAQ:PSTV) Shares Up 2.8% – Time to Buy?

Plus Therapeutics, Inc. (NASDAQ:PSTV)’s share price shot up 2.8% on Friday . The company traded as high as $1.45 and last traded at $1.45. 18,763 shares were traded during trading, a decline of 68% from the average session volume of 58,205 shares. The stock had previously closed at $1.41.

Analyst Ratings Changes

A number of research firms recently commented on PSTV. Ascendiant Capital Markets decreased their target price on Plus Therapeutics from $21.00 to $20.00 and set a “buy” rating on the stock in a research report on Tuesday, September 3rd. HC Wainwright reaffirmed a “buy” rating and set a $8.00 price objective on shares of Plus Therapeutics in a report on Friday, August 16th.

Plus Therapeutics Stock Performance

The business’s fifty day moving average price is $1.44 and its two-hundred day moving average price is $1.73. The stock has a market capitalization of $8.21 million, a P/E ratio of -0.47 and a beta of 0.67.

Plus Therapeutics (NASDAQ:PSTV) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.71) earnings per share for the quarter. The business had revenue of $1.28 million during the quarter. As a group, analysts forecast that Plus Therapeutics, Inc. will post -2 earnings per share for the current year.

Institutional Trading of Plus Therapeutics

A hedge fund recently bought a new stake in Plus Therapeutics stock. AIGH Capital Management LLC bought a new position in Plus Therapeutics, Inc. (NASDAQ:PSTV) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 568,681 shares of the company’s stock, valued at approximately $836,000. AIGH Capital Management LLC owned about 9.98% of Plus Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 3.28% of the company’s stock.

About Plus Therapeutics

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.